GLP-1s for PCOS weight loss: what the evidence actually supports

What did @shestannerthanyou actually say?

Honestly? Not much, medically speaking. The transcript is song lyrics, not health commentary. The actual claim here lives in the caption: that she is "managing my PCOS with a GLP-1." That is the entire medical assertion, and it is worth unpacking carefully because the caption is doing real work with the #pcosinsulinresistance hashtag framing this as a metabolic story, not just a weight loss one.

To be fair to the creator, she did not make any dramatic therapeutic claims in the video itself. She is sharing a personal experience, not prescribing a protocol. But 9,000 viewers are reading that caption and drawing their own conclusions about GLP-1s as a PCOS treatment, which is exactly why this needs a closer look.

Does the science back this up?

Partially, yes. GLP-1 receptor agonists show genuine promise for PCOS, particularly in women with concurrent insulin resistance, but the evidence base is thinner than the TikTok discourse suggests. This is not an FDA-approved indication for any GLP-1 drug as of 2024.

A 2023 randomized controlled trial by Cena et al. in the Journal of Clinical Endocrinology and Metabolism found that semaglutide improved menstrual regularity and reduced androgen levels in women with PCOS and obesity over 24 weeks. A 2022 meta-analysis by Tay et al. in Obesity Reviews confirmed that GLP-1 agonists reduced body weight and fasting insulin in PCOS patients, though sample sizes across studies were small. The insulin-sensitizing mechanism makes biological sense here because insulin resistance drives androgen overproduction in many PCOS phenotypes. But "makes sense" and "proven treatment" are not the same category, and anyone treating their PCOS with a GLP-1 should be doing so under active clinical supervision, not TikTok inspiration.

What did they get wrong (or right)?

She did not get anything factually wrong, because she barely made a factual claim. The caption framing is where things get murky. Calling this "managing my PCOS" implies a therapeutic outcome, which may or may not be happening for her specifically. PCOS has four recognized phenotypes, and GLP-1 benefits are most documented in hyperandrogenic, insulin-resistant presentations. If her PCOS is a different phenotype, the mechanism is less clean.

What she gets right implicitly is that weight loss through GLP-1 use does often improve PCOS symptoms. A 2021 study by Lim et al. in Human Reproduction found that even modest weight reduction of 5 to 10 percent improved ovulation rates and reduced testosterone levels in overweight women with PCOS. So the underlying logic is sound. The problem is the caption presents personal experience as a generalizable strategy, and for a condition as heterogeneous as PCOS, that is a meaningful oversimplification.

What should you actually know?

GLP-1 receptor agonists are not approved by the FDA to treat PCOS. They are approved for type 2 diabetes management and, in higher doses, chronic weight management. Any use for PCOS is off-label, which is legal and sometimes clinically appropriate, but it should be a decision made with a physician who knows your specific labs, not something you pursue because a caption resonated with you.

The insulin resistance connection is real. Roughly 70 percent of women with PCOS have some degree of insulin resistance, per a 2019 review by Rojas et al. in Current Pharmaceutical Design. For that subgroup, addressing insulin dysregulation through GLP-1 agonists or metformin can meaningfully reduce androgen levels and restore menstrual regularity. But PCOS is not one condition. A lean woman with PCOS and normal insulin sensitivity has a different physiological picture, and assuming a GLP-1 will "manage" her condition the same way is not supported by current evidence.

• If you have PCOS and insulin resistance, GLP-1 therapy may be a clinically reasonable option worth discussing with your provider.
• Labs matter. Get a fasting insulin, HOMA-IR, and androgen panel before assuming this approach applies to you.
• Compounded semaglutide is not equivalent to Ozempic or Wegovy. Do not treat them as interchangeable.